BioNxt Solutions Inc. (CSE:BNXT)

Market Cap	40.82M -61.4%
Revenue (ttm)	n/a
Net Income	-9.30M
EPS	-0.08
Shares Out	136.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,500
Open	0.3000
Previous Close	0.3000
Day's Range	0.3000 - 0.3250
52-Week Range	0.2800 - 1.1000
Beta	1.47
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 20
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error